Every material Form 8-K SHOULDER INNOVATIONS, INC. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Shoulder Innovations reported third quarter 2026 net revenue of $16.2 million, up 38% from $11.8 million a year earlier, and a net loss of $7.0 million, narrowed from $8.7 million. The company raised its full-year 2026 net revenue guidance to $68 million to $70 million from $67 million to $69 million, so shareholders see both faster sales growth and a higher outlook, while operating expenses rose.
Q3 2026 net revenue $16.2 million, up 38% from $11.8 million in Q3 2025
Gross margin 78.5% vs. 76.2% a year earlier; operating loss unchanged at $7.6 million
Full-year 2026 net revenue guidance raised to $68 million to $70 million from $67 million to $69 million
Cash, cash equivalents and marketable securities totaled $92.3 million as of September 30, 2026
Shoulder Innovations announced a limited user release of the InSet Go, its next-generation glenoid implant, after the first surgical case was completed at University Hospitals Cleveland Medical Center. The filing contains no financial figures, and the company said it expects a full commercial introduction over the coming quarters, so the news is an early step in the product's rollout.
First surgical case using InSet Go was performed by Robert Gillespie, MD, at University Hospitals Cleveland Medical Center, Cleveland, OH
The company says InSet Go reduces surgical steps and offers the potential for reduced procedure times
Full commercial introduction is expected over the coming quarters, according to CEO Rob Ball
The filing reports no revenue, earnings or guidance figures
Shoulder Innovations announced that Jon Osborne, previously Vice President of Commercial Development, was promoted to Chief Commercial Officer effective August 6, 2026. He will oversee the company's entire commercial organization, which the company says is central to scaling adoption of its shoulder implant portfolio. The filing contains no financial results or guidance.
Jon Osborne promoted to Chief Commercial Officer, effective August 6, 2026
Osborne joined the company as Vice President of Commercial Development in September 2023
Previously held roles at Smith & Nephew Inc. from 2014 to 2023 and at ArthroCare, Tornier USA and Team Surgical from 1998 to 2014
Announced in a press release furnished as Exhibit 99.1 under Regulation FD
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SHOULDER INNOVATIONS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →